Navigation Links
BioMarin to Present at the Wedbush Life Sciences Conference
Date:8/9/2011

NOVATO, Calif., Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces Second Quarter 2011 Financial Results
2. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
3. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
4. BioMarin to Present at the William Blair Growth Stock Conference
5. BioMarin to Present at the Jefferies Global Healthcare Conference
6. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
7. BioMarin Announces First Quarter 2011 Financial Results
8. BioMarin to Present at the Deutsche Bank Healthcare Conference
9. BioMarin to Present at the Barclays Global Healthcare Conference
10. BioMarin to Present at the Cowen Health Care Conference
11. BioMarin to Present at the Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... Point Source Audio® (PSA) , an ... today that the US Patent Office has approved its patent submission that covers ... design creates a lightweight and modular audio headset that has been said to ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, ... the mail from USA Medical Prescription Assistance Program. They are customized to reflect ... mailed package will include a ready-to-use, state-themed card and, in the near future, ...
(Date:4/28/2016)... ... April 28, 2016 , ... For the 10,000 Americans ... smarter about an important part of overall well-being: mental health. Now, a new book—Staying ... promote healthy aging and “cognitive vitality,” which can include everything from honing your memory ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy ... prescription medications from over 180 American pharmaceutical companies for $35 per month, ...
Breaking Medicine News(10 mins):